Previous Close | 0.2000 |
Open | 0.2000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 1.00 |
Expire Date | 2024-12-20 |
Day's Range | 0.2000 - 0.2000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced one oral and four poster presentations at the European Hematology Association (EHA) 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online. The oral presentation includes five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).
As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online. Presentations include five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) for the treatment of relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML), the safety and efficacy of olutasidenib treatment